Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), s477. https://doi.org/10.25251/skin.8.supp.477